Obtaining evidence for use by healthcare payers on the success of chronic obstructive pulmonary disease management

Respiratory Medicine

Volumn 96, Issue SUPPL. 3, 2002, Pages

  Mapel, D ^a   Pearson, M ^b  

^a LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^b UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

Chronic obstructive pulmonary disease; Clinical trials; Healthcare payers; Observational databases

Indexed keywords

PLACEBO;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; DATA BASE; FOLLOW UP; HEALTH CARE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MEDICAL DECISION MAKING; MEDICAL RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SMOKING; STANDARD; CLINICAL TRIAL; DECISION MAKING; ECONOMICS; EVIDENCE BASED MEDICINE; HEALTH PERSONNEL ATTITUDE; INFORMATION PROCESSING; METHODOLOGY; OUTCOME ASSESSMENT; REVIEW;

ATTITUDE OF HEALTH PERSONNEL; CLINICAL TRIALS; DATA COLLECTION; DECISION MAKING; EVIDENCE-BASED MEDICINE; HEALTH CARE COSTS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 0036676207     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(02)80031-2     Document Type: Conference Paper

References (27)

1. Vermeire P. The burden of chronic obstructive pulmonary disease. Respir Med 2002; 96 (Suppl C): S3-S10.
2. Van der Molen T, Pieters W, Bellamy D, Taylor R. Measuring the success of treatment for chronic obstructive pulmonary disease - patient, physician and healthcare payer perspectives? Respir Med 2002; 96 (Suppl C): S17-S21.
3. Buist AS. Guidelines for the management of chronic obstructive pulmonary disease. Respir Med 2002; 96 (Suppl C): S11-S16.
4. ISIS-2 (Second International Study of Infarct Survival) collaborative group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1998; 2: 349-360.
5. Pauwels RA, Löfdahl CG, Pride NB, Postma DS, Laitinen LA, Ohlsson SV. European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): hypothesis and design. Eur Respir J 1992; 5: 1254-1261.
6. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo-controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br Med J 2000; 320: 1297-1303.
7. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977; 1645-1648.
8. Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years observation on male British doctors. Br Med J 1994; 309: 901-910.
9. Jick H, García Rodríguez LA, Pérez-Gutthann S. Principles of epidemiological research on adverse and beneficial drug effects. Lancet 1998; 352: 1767-770.
10. Gompertz P, Irwin P, Morris R, Lowe D, Rutledge Z, Rudd AG, Pearson MG. Reliability and validity of the Intercollegiate Stroke Audit Package. J Evaluation Clin Pract. 2001; 7: 1-11.
11. Bucknall CE, Ryland I, Cooper A, Coutts I, Connolly CK, Pearson MG. National benchmarking as a support system for clinical governance. J Roy Coll Phys Lond 2000; 34: 52-56.
12. Rudd AG, Lowe D, Irwin P, Rutledge Z, Pearson M. National stroke audit - a tool for change? Qual Health Care 2001; 10: 141-151.
13. Roberts CM, Ryland I, Lowe D, Kelly Y, Bucknall CE, Pearson MG. Audit of acute admissions of COPD: standards of care and management in the hospital setting. Eur Respir J 2001; 17: 343-349.
14. Roberts CN, Barnes S, Lowe D, Pearson MG. Death rates in acute admissions of COPD may be related to size of hospital. Eur Respir J 2002 (in press)
15. Thomas M, Pearson M on behalf of the National Monteleukast Survey steering committee. The national monteleukast survey: initial results. Thorax 2001; 56: iii24.
16. Thomas M, Pearson M on behalf of the National Monteleukast Survey steering committee. The national monteleukast survey: methodology. Am J Resp Crit Care Med 2002; 165: A111.
17. Kelsey JL, Thompson WD, Evans AS. Methods in Observational Epidemiology. New York: Oxford University Press, 1986.
18. Coultas DB, Mapel DW, Gagnon R, Lydick E. The health impact of undiagnosed airflow obstruction in a national sample of United States Adults. Am J Respir Crit Care Med 2001; 164: 372-377.
19. National Center for Health Statistics. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-1994. Washington DC: US Government Printing Office, DHHS Publication No. (PHS) 94-1308; 1994.
20. Frost FJ, Hurley JS, Petersen HV, Gunter MJ, Gause D. A comparison of two methods for estimating the health care costs of epilepsy. Epilepsia 2000; 41: 1020-1026.
21. Mapel DW, Hurley JS, Frost FJ, Petersen HV, Picchi MA, Coultas DB. Health care utilization in chronic obstructive pulmonary disease, a case-control study in a health maintenance organization. Arch Intern Med 2000; 160: 2653-2658.
22. Mapel DW, Picchi MA, Hurley JS, Frost FJ, Petersen HV, Mapel VM, Coultas DB. Utilization in COPD, patient characteristics and diagnostic evaluation. Chest 2000; 117: 346S-353S.
23. Mapel, DW, Frost FJ, Coultas DB, Picchi MA, Hurley JS, Petersen HV. Clinical predictors of health care costs and utilization in chronic obstructive pulmonary disease. Eur Respir J 2000; 16: 362S.
24. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S77-S120.
25. Mapel, DW, McMillan GP, Brightwell J, Lydick E, Hurley JA, Petersen HV, Picchi MA, Frost FJ. Predictors of increased healthcare costs in COPD: a prospective analysis. Am J Respir Crit Care Med 2001; 163: A508.
26. Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 580-584.
27. Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC. Survival in COPD patients after regular use of salmeterol and/or fluticasone propionate in general practice. Eur Respir J 2002 (in press).